Announcements Trials
Browse Landscape

Status

Completed 4Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 12Observational 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Blood Specimen Collection 85Surveys and Questionnaires 83Surgical Procedures, Operative 44Drug Therapy 32Radiotherapy 27Biopsy 26Amplified Fragment Length Polymorphism Analysis 24Neoadjuvant Therapy 23Immunohistochemistry 22Gene Expression Profiling 21Bevacizumab 19Data Collection 18Immunotherapy 17Ultrasonography 16Positron Emission Tomography Computed Tomography 16Magnetic Resonance Spectroscopy 16Liquid Biopsy 16pembrolizumab 15Nivolumab 15Watchful Waiting 14Radiosurgery 14Observation 14Microarray Analysis 14Magnetic Resonance Imaging 14Interviews as Topic 14Immune Checkpoint Inhibitors 13Colonoscopy 13Capecitabine 13Polymerase Chain Reaction 12Paclitaxel 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Observational × daratumumab × Clear all
NCT05218603 2022-09-16

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

PETHEMA Foundation

Unknown
100 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡